Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2022Journal of Clinical Oncology

A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPanagiotis A. KonstantinopoulosELElizabeth K. LeeNXNiya Xiong

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Konstantinopoulos et al. (2022) studied this question.

synapsesocial.com/papers/69d98e525e5bcb4e3b837033https://doi.org/10.1200/jco.22.00628
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)2020 · 1,034 citations
  2. 2Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer2020 · 55 citations
  3. 3Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study2019 · 79 citations
  4. 4Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma2015 · 326 citations